Chemoembolization for hepatocellular carcinoma: Effect of intraarterial lidocaine in peri- and post-procedural pain and hospitalization(105 visite) Romano M, Giojelli A, Tamburrini O, Salvatore M
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2003 Apr; 105(4): 350-355.
Tipo di articolo: Journal Article,
Impact factor: 1.368, Impact factor a 5 anni: 1.47
Parole chiave: Anaesthetics, Local Administration And Dosage, Hepatocellular Carcinoma, Liver Neoplasms, Chemoembolization, Cisplatin, Epirubicin, Gelfoam, Iodinated Poppyseed Oil, Lidocaine, Narcotic Analgesic Agent, Sodium Chloride, Tramadol, Adult, Article, Artificial Embolism, Blood Flow, Clinical Article, Controlled Study, Drug Safety, Emulsion, Female, Fever, Hepatic Artery, Hospitalization, Human, Liver Cell Carcinoma, Nausea And Vomiting, Pain Assessment, Post Embolization Syndrome, Side Effect, Statistical Significance, Visual Analog Scale, Abdominal Pain, Anesthetics, Therapeutic, Chi-Square Distribution, Injections, Intra-Arterial, Length Of Stay, Middle Aged, Pain Measurement, Treatment Outcome,
Affiliazioni:
*** IBB - CNR *** Dipto. Assistenziale Radiol./R., Universita Federico II, Napoli, Italy Ist. di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, Napoli, Italy Unità Operativa di Radiologia, Universita Magna Graecia, Catanzaro, Italy Via Luca da Penne, 3, 80122 Napoli NA, Italy Unit Operativa di Radiologia, Universita Magna Graecia, Catanzaro, Italy
Riferimenti:
El-Serang, H.B., Mason, A.C., Rising incidence of hepatocellular carcinoma in the United States (1999) N Engl J Med, 340, pp. 745-75
Patt, C.H., Thuluvath, P.J., Role of liver transplantation in the management of hepatocellular carcinoma (2002) J Vasc Interv Radiol, 13, pp. 205-210
Llover, Jm., Fuster, J., Bruix, J., Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation (1999) Hepatology, 30, pp. 1434-1440
Teratani, T., Ishikawa, T., Shiratori, Y., Hepatocellular carcinoma in elderly patients: Beneficial therapeutic efficacy using percutaneous ethanol injection therapy (2002) Cancer, 95, pp. 816-823
Shibata, T., Iimuro, Y., Yamamoto, Y., CT-guided transthoracic percutaneous ethanol injection for hepatocellular carcinoma not detectable with US (2002) Radiology, 223, pp. 115-120
Poon, R.T., Fan, S.T., Tsang, F.H., Locoregional therapies for hepatocellular carcinoma: A critical review from the surgeon's perspective (2002) Ann Surg, 235, pp. 466-486
Shiina, S., Teratani, T., Obi, S., Nonsurgical treatment of hepatocellular carcinoma: From percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation (2002) Oncology, 62, pp. 64-68
Lencioni, R., Paolicchi, A., Bartolozzi, C., Percutaneous alcohol administration for hepatocarcinoma: Long-term results (1997) Radiol Med, 94, pp. 8-13
Dalla Palma, L., Pozzi Mucelli, R., Sponza, M., Diagnostic imaging and interventional therapy in hepatocarcinoma. Multicenter study of 290 cases (1997) Radiol Med, 94, pp. 30-36
Clouse, M.E., Lee, R.G.L., Duszlak, E.J., Peripheral hepatic artery embolization for primary and secondary hepatic neoplasms (1983) Radiology, 147, pp. 407-411
Cammà, C., Schepis, F., Orlando, A., Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials (2002) Radiology, 224, pp. 47-54
Hartnell, G.G., Gates, J., Stuart, K., Hepatic chemoembolization: Effect of intraarterial lidocaine on pain and post-procedure recovery (1999) Cardiovasc Intervent Radiol, 22, pp. 293-297
Lee, S.H., Hahn, S.T., Park, S.H., Intraarterial lidocaine administration for relief of pain resulting from transarterial chemoembolization of hepatocellular carcinoma: Its effectiveness and optimal timing of administration (2001) Cardiovasc Intervent Radiol, 24, pp. 368-371
Molgaard, C.P., Teitelbaum, G.P., Pentecost, M.J., Intraarterial administration of lidocaine for analgesia in hepatic chemoembolization (1990) J Vasc Interv Radiol, 1, pp. 81-85
Huskisson, E.C., Measurement of pain (1974) Lancet, 2, pp. 1127-1131
Moore, R.M., Singleton, A.O., Studies on the pain-sensibility of arteries. II. Peripheral paths of afferent neurons from the arteries of the extremities and of the abdominal viscera (1988) Am J Physiol, 104, pp. 267-276
Purpose. To assess the efficacy of intraarterial lidocaine on peri- and post-procedural pain and on length of hospital stay in hepatocellular carcinoma (HCC) patients undergoing chemoembolization. Materials and methods. Twenty-eight patients (19M, 9F, age range 49-76) who underwent hepatic chemoembolization at our Institution between March 2000 and February 2002 were included in the study. Group A consisted of 14 patients who received intraarterial lidocaine immediately before and during chemoembolization, while in the 14 patients of group B lidocaine was substituted with saline solution. The doses of centrally acting narcotics (tramadol) administered periprocedurally and in the three days following the procedure were compared, as were the hospitalization times. Subjective pain was measured using the visual analogue scale. Chemoembolizations were performed with an emulsion of lipiodol, cisplatin and epirubicin followed by embolizing material (gelfoam of Contour particles) in order to achieve complete blood flow stop in the proper hepatic artery. Results. No side effects were noted that could be due to systemic administration of lidocaine. All patients experienced some degree of post-embolization syndrome. Periprocedural, day 1 and day 2 post chemoembolization dosages of tramadol were significantly lower in group A with respect to group B patients. No group A patient required analgesia on day 3. No statistical difference was observed in time persistence of nausea and vomiting, fever and hospitalization time between the two patient groups. Conclusions. Intraarterial administration of lidocaine before and during chemoembolization is a safe and effective method for preventing or reducing peri- and post-procedural pain and dosage of narcotic analgesics in patients with HCC. Hospitalization times did not differ significantly between the two groups, probably because of the other components of post-embolization syndrome, such as fever, nausea and vomiting.
59 Records (56 escludendo Abstract e Conferenze). Impact factor totale: 200.405 (191.496 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 210.527 (201.042 escludendo Abstract e Conferenze).
ibb.cnr.it